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In overt diabetic nephropathy (DNP), an increase in the
permeability of the glomerular basement membrane (GBM)
has been associated with a loss of negatively charged
heparan sulfates (HS) in the GBM. Heparanase (HPSE), an
endo-b(1-4)-D-glucuronidase, can cleave HS and could be a
potential candidate for the degradation of glomerular HS,
leading to the development of proteinuria. We analyzed
whether changes in HS expression are associated with HPSE
expression in overt DNP. Immunofluorescence staining was
performed to analyze HS, HPSE, and agrin core protein
expression in kidney biopsies from patients with overt DNP
and from rats and mice with streptozotocin (STZ)-induced
diabetes. We also investigated the effect of transgenic
HPSE overexpression in mice on glomerular HS and agrin
expression. We demonstrate that the loss of GBM HS (50%)
and tubular HS (60%) is associated with a four-fold
increased HPSE expression in overt DNP. In addition,
glomerular HPSE expression is upregulated in rats
(messenger RNA (mRNA) 2.5-fold, protein three-fold) and
mice (mRNA seven-fold, protein 1.5-fold) with STZ-induced
diabetes. Furthermore, transgenic HPSE overexpression
results in disappearance of HS, whereas expression of the
core protein agrin remains unaltered. Our observations
suggest that HPSE is involved in the pathogenesis of
proteinuria in overt DNP by degradation of HS.
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Diabetic nephropathy (DNP) develops in patients with type I
(insulin-dependent) or type II (non-insulin-dependent) dia-
betes mellitus and is the most common cause of end-stage
renal disease in the western world.1,2 In the early phase of
human DNP, there is a preferential urinary loss of albumin,
consistent with a loss of negatively charged heparan sulfates
(HS) in the glomerular basement membrane (GBM). Several
human and experimental studies have shown that a reduction
of glomerular HS was associated with an increased perme-
ability of proteins through the GBM. Heparitinase digestion
of glomerular HS resulted in an increased permeability for
native albumin and ferritin in rats.3,4 Administration of a
monoclonal antibody against HS caused massive albuminuria
in rats.5 Importantly, a decrease of HS side chains in the
GBM has been described in human DNP, which was inversely
correlated with the degree of albuminuria.6,7 Finally, treat-
ment with heparin or heparinoids in experimental and
human DNP prevented loss of GBM anionic sites and
reduced albuminuria.8,9
Several mechanisms could lead to the reduction of HS in
proteinuric diseases:10 (1) masking of HS by immune
complexes;11 (2) HS depolymerization by radicals;12 (3)
hyperglycemia-induced reduction of both HS expression and
HS sulfation;13 (4) complement-mediated cleavage of HS;14
and (5) proteolytic cleavage of the HS attachment site on
heparan sulfate proteoglycans by enzymes.15
We hypothesize that the HS-specific endo-b-D-glucuroni-
dase heparanase (HPSE) can be involved in the degradation of
HS in overt DNP. HPSE catalyzes the hydrolytic cleavage of the
b(1,4)-glycosidic bond between glucuronic acid and glucosa-
mine residues within HS.16 HS degradation by HPSE results in
the release of many HS-bound molecules including growth
factors, extracellular matrix molecules, enzymes, enzyme
inhibitors, chemokines, and cytokines, which are involved in
processes such as extravasation, growth, and chemotaxis of
cells. In addition, cleavage of HS chains leads to disassembly of
the basement membranes and facilitates cell migration and
invasion of tumor cells into tissues.16,17 Besides its role in
extracellular matrix degradation, HPSE is also involved in
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many other biological and pathological processes, such as liver
development, embryonic development, cell differentiation, cell
growth, morphogenesis, tissue repair, tumor metastasis,
angiogenesis, and inflammation.18–20
Recent studies revealed that HPSE could be involved in the
degradation of HS within the GBM, leading to proteinuria in
several (experimental) proteinuric diseases. It has been
demonstrated that HPSE activity is increased in the urine
of patients with type 1 diabetes.21,22 Several experimental
studies showed that glomerular HPSE expression was
upregulated in rats with puromycin aminonucleoside ne-
phrosis,23 in passive Heymann nephritis (PHN)24 and in a
model of accelerated anti-GBM disease.25 Administration of
the HPSE inhibitor PI-88 to rats with PHN reduced
proteinuria almost two-fold, which was associated with
preservation of the amount of HS in the GBM.26 Transgenic
overexpression of HPSE in mice resulted in proteinuria,
which was accompanied by effacement of podocyte foot
processes.27 Involvement of glomerular HPSE has also been
demonstrated in patients with minimal change disease
(Rutjes et al., submitted) and HPSE activity was increased
in the urine of children with steroid-sensitive nephrotic
syndrome.28 A recent study demonstrated an upregulation of
HPSE in the glomeruli of patients with DNP. Additionally,
in vitro data in this study demonstrated that high glucose was
able to induce HPSE expression in podocytes, which was
associated with a slight reduction of cell surface HS.29
In this study, we evaluated whether changes in glomerular
HS are associated with an increased HPSE expression in overt
DNP. We demonstrated a correlation between glomerular HPSE
and HS expression in patients with DNP. In streptozotocin
(STZ)-induced diabetes in rats and mice, both glomerular
HPSE messenger RNA (mRNA) and protein expression were
upregulated. Finally, we found that transgenic overexpression of
HPSE, leads to loss of glomerular HS expression, whereas the
expression of the agrin core protein did not change.
RESULTS
Expression of HPSE in human diabetic nephropathy
Clinical characteristics of the diabetic patients are presented
in Table 1. We evaluated the expression of HS, HPSE, and
agrin, by indirect immunofluorescence in kidney biopsies
from macroalbuminuric diabetic patients and normal con-
trols (Figure 1). In control kidney sections, a linear staining
of the core protein of agrin and HS was observed along the
GBM, which fully co-localized (Figure 1a). However, in the
glomeruli of patients with DNP, a decreased staining of HS
along the GBM was observed, whereas the expression of the
core protein of agrin in the GBM did not change (Figure 1c).
Glomerular HPSE expression was increased in patients with
DNP (Figure 1d), whereas in the normal human kidney, only
a weak staining of HPSE could be observed (Figure 1b).
Table 1 | Clinical characterization of patients with type II diabetes and overt DNP included in this study
Patient Age (years) Gender Duration of diabetes (years) HbA1c (%) Systolic BP (mm Hg) Diastolic BP (mm Hg)
Proteinuria
(g/24 h)
1 66 M 44 6.8 180 80 2.4
2 59 F 28 7.8 190 110 5.0
3 71 M 43 6.2 150 90 4.6
4 76 M 5 7.3 150 70 18.0
5 51 F 4 8.8 160 80 2.4
6 65 M 20 7.2 120 65 4.1
7 49 M 412 6.4 160 85 15.9
8 59 F 19 7.4 130 70 6.1
9 57 M 20 NA 186 75 3.0
10 64 F 14 NA 150 70 3.0
11 64 F 7 6.0 160 90 3.5
BP, blood pressure; DNP, diabetic nephropathy; F, female; M, male; NA, not available.
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Figure 1 | Expression of HS, HPSE, and agrin in human DNP.
Immunofluorescence double stainings of (a and c) agrin (red) with
HS (green) and (b and d) HS (green) with HPSE (red) in kidney
sections from (c and d) patient with overt DNP and (a and b) a
control. (a) Co-staining of agrin with HS revealed a linear co-
localization (yellow) along the GBM in controls, (c) whereas reduction
of glomerular HS was observed in patients with DNP. Decrease of
glomerular HS expression in diabetic patients was associated
with an upregulation of HPSE in the glomeruli of (d) diabetic patients
compared to (b) controls. Original magnification  63.
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In Figure 2, we present the quantitative analysis of the
expression of HS and HPSE. In the glomeruli, HS was
significantly decreased in patients with DNP (Po0.001,
Figure 2a), which was associated with an increased HPSE
expression (Po0.001, Figure 2b). A similar change was found
in the tubular expression of HS and HPSE (Po0.001, Figure
2c and d). In this study, we found an inverse correlation
between GBM HS expression and the degree of proteinuria
(Figure 2e; r¼0.56, Po0.001), which is in line with our
previous results.6 In addition, we observed a correlation
between glomerular HS and HPSE expression (Figure 2f;
r¼0.29, Po0.05).
To evaluate the localization of the increased glomerular
HPSE expression in diabetic patients, we performed double
stainings with HPSE and antibodies against epitopes localized
in the GBM (agrin), podocytes (synaptopodin), and
mesangial cells (perlecan). Staining of HPSE co-localizes
partly with agrin (Figure 3a), as well as with synaptopodin
(Figure 3b), but not with perlecan (Figure 3c). The staining
along the GBM with agrin reveals the extracellular presence
of HPSE, whereas the staining with synaptopodin supports
the intracellular localization of HPSE in podocytes. Further-
more, the positive staining of HPSE within some capillary
loops suggests that also endothelial cells express HPSE. We do
have unpublished data that conditionally immortalized
mouse glomerular endothelial cells,30 and podocytes express
HPSE both at the mRNA and protein level.
To define more precisely in which tubular segment HPSE
was mainly localized, we performed co-stainings of HPSE
with markers for specific segments of the tubular system, that
is proximal tubules (P-glycoprotein), distal convoluted
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Figure 2 | Quantitative analysis of HS and HPSE expression
in human DNP. Staining of HS and HPSE was scored by three
independent observers on a scale between 0 and 10 for HS linearity
or on a scale between 0 and 5 for HPSE intensity in arbitrary units
(a.u.). Points represent mean scores from each individual glomerulus
or tubular photograph and horizontal lines represent median values
of these scores. HS expression was significantly reduced both in
(a) glomeruli and (c) tubuli, whereas expression of HPSE was
increased in both (b) glomeruli and (d) tubuli of patients with overt
DNP compared to the controls. There was an inverse correlation
between (e) glomerular HS and proteinuria and between (f)
glomerular HS and glomerular HPSE expression. ***Po0.001.
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Figure 3 | Localization of HPSE in human DNP.
Immunofluorescence double staining of HPSE with glomerular
markers for the GBM (agrin), podocytes (synaptopodin), or mesangial
cells (perlecan) in a patient with overt DNP. HPSE expression
co-localizes with both (a) agrin and (b) synaptopodin, representing
the extracellular and intracellular HPSE expression, respectively.
(c) However, HPSE is not expressed by mesangial cells. (d) Tubular
HPSE is mainly expressed in proximal tubuli, determined by
co-staining with anti-P-glycoprotein. Original magnification  63.
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tubules (calbindin D-28k), and the collecting ducts (aqua-
porin-2). As shown in Figure 3d, HPSE expression was
mainly localized in the proximal tubules identified with anti-
P-glycoprotein in both controls and diabetic patients. HPSE
expression did not co-localize with calbindin D-28 k and
aquaporin-2 (data not shown).
HPSE expression in rats and mice with STZ-induced diabetes
Five months after the induction of diabetes in rats, we
observed an increased staining of glomerular HPSE com-
pared to controls, which was accompanied by a reduction of
GBM HS (Figure 4a). Increased HPSE protein expression in
rats with STZ-induced diabetes was confirmed by Western
blot analysis. In renal cortex of diabetic rats, the 50 kDa
subunit, which is the active form of HPSE, was present,
whereas it was undetectable in controls (Figure 4b).
Quantification of immunofluorescence stainings showed that
HS expression was reduced in diabetic rats. However, loss of
HS expression in the GBM did not reach statistical
significance (Figure 4c). Furthermore, both HPSE protein
(immunofluorescence) as well as mRNA expression were
significantly increased in diabetic rats compared to controls
(Po0.05, Figure 4d). In diabetic mice, we also observed
elevated levels of HPSE mRNA (seven-fold; Po0.01)
compared to controls (Figure 5a). In addition, glomerular
HPSE protein expression was also significantly increased
(Po0.05, Figure 5b), although glomerular HS expression was
not significantly reduced (P40.05, Figure 5c). Interestingly,
the decrease of HS expression correlated with both the
elevated HPSE protein expression (Figure 5d; r¼0.82,
Po0.05) and HPSE mRNA expression (data not shown;
r¼0.72, Po0.05).
Transgenic overexpression of HPSE in mice
To investigate whether overexpression of HPSE is associated
with a decrease of glomerular HS expression, we stained
kidney sections from mice with transgenic overexpression of
HPSE (HPSEtg) with specific antibodies. Overexpression of
HPSE was observed in both tubuli and glomeruli of
transgenic mice compared to controls, which resulted in an
almost complete absence of the expression of HS (Figure 6a).
This underlines the importance of HPSE for HS degradation.
Next, we evaluated whether HPSE overexpression affects the
expression of the core protein of agrin, to which HS is
attached. No differences in expression of the core protein of
agrin were observed between HPSEtg mice and controls
(Figure 6a). Expression of perlecan and collagen IV in
HPSEtg mice also remained unchanged (data not shown). In
addition, we observed a significant increase in urinary
albumin excretion in HPSEtg mice compared to controls
(Figure 6b). To mimic the effect of HPSE overexpression, we
applied recombinant active HPSE to normal mouse kidney
sections. Similar to the in vivo situation with transgenic
overexpression of HPSE, we observed an almost complete
disappearance of HS, whereas the expression of the core
protein of agrin was unaffected (Figure 6c).
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Figure 4 | HS and HPSE expression in rats with STZ-induced
diabetes. (a) Immunofluorescence staining of the increased HPSE
expression and decreased HS expression in kidneys of diabetic rats.
(b) Western blot analysis was used to confirm an increased HPSE
protein expression in renal cortex of rats with STZ-induced diabetes
compared to controls. (c) HS expression was decreased, however, no
statistical significance could be observed. (d) Quantification revealed
that both HPSE protein and HPSE mRNA expression were
upregulated in glomeruli of diabetic rats compared to controls.
Horizontal lines represent median values. *Po0.05. a.u. arbitrary
units; rHPSE, recombinant heparanase.
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DISCUSSION
We demonstrate that the reduction of HS moieties in the
glomeruli of patients with type II diabetes and overt DNP is
correlated with an upregulation of HPSE. This association
has been suggested previously in studies that describe an
increased HPSE expression in experimental models of
proteinuria, such as PHN, puromycin aminonucleoside
nephropathy, and anti-GBM nephritis.23–25 Inhibition of
HPSE in PHN by PI-88 reduced proteinuria and partly
preserved HS staining, which suggests that HPSE is at least
partly responsible for the development of proteinuria.26
Recently, it has been reported that glomerular HPSE
expression was increased in patients with DNP. However,
needle biopsies from autopsy specimens were used and renal
HS expression was not evaluated.29 We found a correlation
between the loss of HS and the expression of HPSE in
the glomeruli, which suggest that HPSE is responsible for the
glomerular degradation of HS and, possibly, for the
development of proteinuria in overt human DNP.
These data are further supported by our observations in
the STZ-induced diabetes model (model for type I diabetes)
in rats and mice. Both HPSE mRNA and protein expression
were increased in diabetic rats and mice, which was
associated with a decrease in HS expression. In mice with
STZ-induced diabetes, this HS expression was correlated with
both HPSE mRNA and protein expression. However, this
decrease in HS expression did not reach statistical signifi-
cance. This is in line with our previous observation in this
model using JM403 for HS staining, in which only a relative
decrease of HS compared to increased collagen IV content of
the GBM was observed.13,31 JM403 reacts with free amine
groups in glucosamine,32 and a decrease in N-sulfation
(leading to an increased staining) may compensate a decrease
in staining owing to a decrease in the amount of HS. This
possibility is underlined by our observation that in basement
membranes of capillary muscles, an increased staining of
JM403 was found in diabetic patients with normo- and
microalbuminuria, whereas in patients with macroalbumi-
nuria staining was decreased.33
Recently, we obtained evidence that in the very early phase
of DNP (i.e. microalbuminuria) glomerular HS was not
decreased.34,35 This was also suggested by a study of Vernier
et al.,36 which demonstrated that cuprolinic blue staining in
the GBM was not decreased in microalbuminuria, suggesting
that decrease of glomerular HS starts in more advanced
phases of DNP, as we have found in this study. Previously, we
demonstrated that HS expression was decreased in the
dermal basement membrane in skin biopsies from patients
with DNP.37 Preliminary data show that HS expression in
skin biopsies from diabetic patients normalized after
succesful pancreas transplantation, suggesting that changes
in HS are reversible if euglycemia is restored.
Glomerular HPSE expression in patients with overt DNP
is mainly localized in podocytes and endothelial cells. This is
supported by observations that podocytes and endothelial
cells are the main cell types that express and release
HPSE.23,26 It is not clear yet what drives the increased HPSE
expression in these cells, but there are some clues which
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Figure 5 | HS and HPSE expression in mice with STZ-induced
diabetes. (a) Renal cortex of mice with STZ-induced diabetes
contained a significantly higher amount of HPSE mRNA compared
to controls. (b) HPSE protein expression was significantly increased
and (c) HS expression was decreased, although not significant.
Sections were coded randomly and staining was evaluated by two
independent observers on a scale of 0–10 for HS linearity and on a
scale of 0–5 for HPSE staining intensity. Horizontal lines represent
median values. (d) HS expression inversely correlated with HPSE
mRNA expression. **Po0.01, *Po0.05. a.u.; arbitrary units.
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Figure 6 | Glomerular expression of HPSE, HS, and agrin in mice
with transgenic HPSE overexpression and after treatment with
active HPSE. (a) HPSE expression is increased in the HPSEtg mouse
kidney compared to the control. (a) HS expression was markedly
reduced in the kidney of mice with transgenic overexpression of
HPSE, whereas agrin core protein expression did not differ. (b) A
significant increase in the urinary albumin excretion was observed in
HPSEtg mice compared to controls. (c) After exposure of kidney
sections to recombinant active HPSE, HS staining almost completely
disappeared, whereas it did not affect agrin expression. Original
magnification  100. *Po0.05.
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mechanisms may be operative. Recently, it was demonstrated
that high glucose was able to increase HPSE expression in
podocytes, which was associated with a reduction of cell
surface HS.29 Another possible factor able to induce HPSE
expression and activity may be angiotensin II. We have
preliminary unpublished data that angiotensin II induces
HPSE mRNA expression in cultured mouse podocytes. This
is further corroborated by our observation that angiotensin-
converting enzyme inhibition in adriamycin nephropathy
prevents loss of HS from the GBM38 and that angiotensin II
receptor 1 blockade reduces increased HPSE expression,
restores HS loss from the GBM, and reduces proteinuria in
the same model.39 Finally, reactive oxygen species, especially
hydroxyl radicals, are involved in the development of
proteinuria in adriamycin nephropathy.12 Recently, we found
that besides depolymerization of HS,12 HPSE was also
upregulated in this model, which could be prevented by the
hydroxyl scavenger dimethylthiourea.39 Currently, we are
trying to elucidate the mechanisms that could be involved in
a disturbed expression of HPSE in overt DNP and other non-
diabetic glomerulopathies.
HPSE expression was also observed in the cytoplasm of
proximal tubules in both controls and diabetic patients. The
presence of HPSE in tubuli of normal subjects suggests that
HPSE is also involved in the normal physiology of these cells.
In diabetic patients, increased urinary HS has been
reported.40,41 As tubular HPSE expression is increased in
diabetic patients, it is possible that the increased urinary
excretion of HS originates from tubuli rather than from the
glomerulus.
Additionally, we demonstrate that transgenic HPSE over-
expression results in a markedly reduced glomerular HS
expression, whereas agrin core protein expression remains
unchanged. As described previously and confirmed in this
study, transgenic overexpression of HPSE resulted in an
increased urinary protein excretion,27 which, along with our
findings provides further evidence for a possible involvement
of HPSE in the development of proteinuria. The reduction of
HS expression in HPSEtg mice was mimicked by treating
kidney sections with HPSE, supporting that the decrease of
HS was secondary to HPSE overexpression. Very recently,
HPSE knockout mice have been generated and induction of
diabetes into this model would be interesting to further
elucidate the role of HPSE in the pathophysiology of DNP
(Dr JP Li, Uppsala, Sweden, personal communication).
We (yet unpublished) and others observed that heparin
and several low molecular weight heparins can inhibit the
enzymatic activity of HPSE.42–47 Both experimental and
clinical studies have shown that these heparin(oid)s can
reduce proteinuria in both microalbuminuric and macro-
albuminuric DNP (reviewed by Gambaro and van der
Woude48). In experimental DNP, Gambaro et al.9 showed
that treatment with sulodexide reduced albuminuria, pre-
vented GBM thickening and loss of HS from the GBM. At
that time, it was not clear how this beneficial effect was
exerted. Sulodexide can inhibit HPSE, so it is conceivable that
this explains the renoprotective effect of sulodexide. In
addition, the HPSE inhibitor PI-88 was able to reduce
proteinuria in PHN nephritis.26 Unfortunately, these com-
pounds do not only inhibit HPSE activity, but also exert
other effects such as anti-coagulant activities. Recently, some
well-defined specific HS-based HPSE inhibitors have been
developed, but these compounds have a very short half-life of
about 4 h, which makes it very difficult to study long-term
HPSE inhibition in vivo in experimental DNP (I Vlodavsky;
yet unpublished results). Nevertheless, inhibition of HPSE
has already been successfully applied in cancer treatment for
its anti-metastatic potential.49 Therefore, it remains to be
determined whether inhibition of biological actions of HPSE
in vivo with non-coagulant heparinoids is a feasible goal for
therapy in DNP.
In conclusion, our data demonstrate that increased
glomerular HPSE expression in human and experimental
DNP and in mice with transgenic overexpression of HPSE is
associated with a decrease of HS in the GBM and
albuminuria. These data suggest that increased HPSE
expression could be responsible for the decrease of HS in
the GBM and the development of proteinuria. The observed
anti-proteinuric effects of low molecular weight heparins in
DNP underscore this idea.48 Elucidation of the signals and
underlying mechanisms that lead to HPSE overexpression by
specific glomerular cell types may provide new clues for the
generation of drugs against the development of DNP.
MATERIALS AND METHODS
Human renal tissue
We evaluated renal biopsies from 11 patients with overt DNP from
patients with type II diabetes mellitus. Control renal tissue was
obtained from five non-diabetic individuals, from donor kidneys for
anatomical reasons not suitable for transplantation, and from a
normal part of kidneys removed for renal adenocarcinoma. Clinical
characteristics of the diabetic patients are presented in Table 1. The
Human Ethics Review Committee of the Academic Medical Center
Amsterdam approved the analysis of the human kidney biopsies.
Animal models
Rats. Diabetes was induced in male Wistar–Mu¨nich rats (n¼ 4;
Jackson Laboratory, Bar Harbor, USA) by intravenous injection of
STZ (55 mg/kg body weight). Sex- and age-matched control rats
(n¼ 4) received saline. Blood glucose levels were maintained around
B25 mmol/l by treatment with 1.2 IU of bovine insulin (Ultralente;
Novo, Copenhagen, Denmark) three times a week. Body weight,
blood glucose, urine production, and albuminuria were measured as
described previously.13 Characteristics are listed in Table 2. Five
months after the induction of diabetes, rats were killed and kidneys
were processed for analysis.
Mice. C57Bl6/J female mice (n¼ 6; Harlan, Horst, The Nether-
lands) were injected intraperitoneally with 200 mg/kg body weight
STZ in 10 mM citrate buffer (pH 4.6). Controls (n¼ 4) received
citrate buffer only. Blood glucose levels were measured every 3 days
and urine samples were collected at 2, 4, 6, 9, 11, and 13 weeks after
induction of diabetes to determine albuminuria as described
previously.50 Slow release insulin pellets (Linshin Canada Inc.,
Ontario, Canada) were implanted subcutaneously when blood
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glucose rose above 20 mmol/l. Mice were not ketotic and were killed
after 17 weeks of diabetes and tissue samples were processed for
analysis. Characteristics are listed in Table 2.
In addition, kidney tissue was analyzed from transgenic mice,
which overexpress HPSE in all tissues.27 Radial immunodiffusion, as
described previously,51,52 was used to determine albuminuria in
HPSEtg mice (n¼ 11) and controls (n¼ 9). Urinary creatinine was
measured enzymatically (Roche Diagnostics, Penzberg, Germany)
and urinary albumin excretion was expressed as the ratio: mg
albumin/mg creatinine. The local Animal Ethical Committees
approved the animal experiments.
RNA isolation and real-time reverse transcription-polymerase
chain reaction
Total RNA was isolated from rat and mouse kidney tissue using the
RNeasy mini-kit (Qiagen Benelux, Venlo, The Netherlands). In rats,
mRNA was isolated from purified glomeruli53 and in mice from
renal cortex. One microgram of RNA was reverse transcribed into
cDNA using Oligo-dT priming and Superscript reverse transcriptase
(Invitrogen Life Technologies, Breda, The Netherlands). HPSE
expression was quantified by real-time polymerase chain reaction
using iQTM SYBRs Green Supermix and the MyiQTM real-time
polymerase chain reaction system (Bio-Rad Laboratories, Veenen-
daal, The Netherlands). Polymerase chain reaction conditions:
denaturation at 951C for 3 min, followed by 40 cycles of 951C for
15 s, 571C for 30 s, and 721C for 30 s and finally elongation at 721C
for 10 min. Rat primers: HPSE: forward (F) 50-gaagcaaactccgagtgtac-
30, reverse (R) 50-ggtttgaccgttcagttgg-30; RNA polymerase II: (F)
50-gactttgatgacgtggagg-30, (R) 50-ggtcgttcaccagatgggag-30. Mouse
primers: HPSE: (F) 50-ggagcaaactccgagtgtatc-3’, (R) 50-cagaatttgaccgt
tcagttgg-30; b-actin: (F) 50-gtgggccgctctaggcaccaa-30, (R) 50-ctctttgat
gtcacgcacgatttc-30; RNA polymerase II: (F) 50-caccacgtccaatgatattgtgg-30,
(R) 50-gtgctgctgcttccataagg-30 (Biolegio BV, Malden, The Netherlands).
Expression of the housekeeping genes b-actin and/or RNA polymerase II
was used to quantify HPSE expression by the delta-delta cycle time (Ct)
method.
Immunofluorescence staining and HPSE treatment of mouse
kidney sections
Human DNP. Kidney biopsy sections (5mm) were fixed in
100% acetone for 10 min at 41C. Sections were incubated with
primary antibodies (all listed in Table 3) diluted in phosphate-
buffered saline (PBS) for 1 h at room temperature, washed twice in
PBS, and incubated with the appropriate secondary antibodies
diluted in PBS containing 4% normal human serum and 4% normal
goat serum for 1 h at room temperature. Subsequently, sections were
washed in PBS, embedded in Vectashield mounting medium H-1000
(Vector Laboratories Inc., Burlingame, CA, USA) and examined
with confocal laser scanning microscopy (CLSM; Leica, Heidelberg,
Germany). At least three glomeruli per section were evaluated by
three independent observers. For agrin and HS expression, linearity
of the GBM was scored at an arbitrary scale of 0–10 (arbitrary units
(a.u.); 0¼ no staining, 1¼ 10% linear GBM staining, etc., with a
maximum score of 10 for 100% linearity) and for HPSE expression,
a scale of 0–5 was used for staining intensity. Scoring between the
three different observers was consistent, because regression analysis
yielded a good correlation for the scores of HS (r2¼ 0.84, r2¼ 0.83,
r2¼ 0.84; all Po0.001) and HPSE (r2¼ 0.80, r2¼ 0.74, r2¼ 0.79; all
Po0.001).
To investigate which cell type could be responsible for the
expression of HPSE in the glomeruli of patients with DNP,
immunofluorescence double stainings with HPSE were performed
as described above, except that antibodies were diluted in PBS with
1% bovine serum albumin. Synaptopodin was used as a podocyte
marker, agrin was used to distinguish between the inside and the
outside of the glomerular capillaries, and perlecan was used as a
marker for the mesangium. To test in which tubuli from both
controls and patients with DNP expression of HPSE was observed,
we performed immunofluorescence double stainings with HPSE and
a marker for proximal tubuli (P-glycoprotein), a marker for distal
convoluted tubuli (calbindin D-28k) or aquaporin 2, which
recognizes the collecting duct (Table 3).
Experimental DNP and HPSE treatment. HS, agrin, and HPSE
expression was determined in kidneys of rats and mice with STZ-
induced diabetes, in kidneys of mice with HPSE overexpression, and
in normal mouse kidney tissue after treatment with HPSE. Sections
(2mm) were fixed in 100% acetone for 10 min at 41C. For treatment
of normal mouse kidney tissue with active HPSE, unfixed kidney
sections were incubated with 0.22 mg/ml active recombinant mouse
HPSE54 for 2 h at 371C in 50 mM sodium acetate buffer (pH 5) after
which sections were washed in PBS and fixed for 10 min in 100%
acetone at 41C. Staining of HS, HPSE, and the agrin core protein
was performed as described above. Normal goat serum (4%) and
normal rat serum (4%) were added to the secondary antibodies on
rat sections. To detect HS on mouse kidney tissue, we labeled our
monoclonal antibody JM403 with digoxigenin (DIG; Roche
Diagnostics, Penzberg, Germany). Sections were coded randomly
and evaluated by two independent observers as described above.
Western blot analysis
Renal cortex from rats with STZ-induced diabetes and controls was
lysed in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Triton X-100
(Sigma, Zwijndrecht, The Netherlands), and ethylenediaminetetra-
acetic acid-free protease inhibitors (Roche). Equal amounts of total
Table 2 | Characteristics of rats and mice with STZ-induced diabetes and controls
Rats (5 months) Mice (17 weeks)
Parameters Controls (n=4) Diabetic (n=4) Controls (n=4) Diabetic (n=6)
Body weight day 0 (g) 211713.0 211711.0 22.772.0 22.471.0
Body weight at sacrifice (g) 365736.0 268730.0* 27.973.4 24.471.6
Blood glucose (mmol/l) 3.970.2 21.171.3* 7.471.5 24.871.8*
Albuminuria 0.3 (0.1–0.6)a 39.3 (33.1–64.4)a,* 43 (29.5–59)b 135.5 (83.5–169)b,*
STZ, streptozotocin.
Data are given as means7s.d. or as medians (range).
*Po0.05 compared to rat or mice controls.
aAlbuminuria (mg/24 h).
bAlbuminuria (mg/g creatinine).
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protein (3 mg; determined with bicinchoninic acid (Sigma)) were
incubated overnight at 41C with 100ml of washed heparin-agarose
beads (Sigma).55 Beads were washed in PBS and then boiled in
100ml Laemli sample buffer. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis was performed and proteins were transferred to a
polyvinylidene difluoride membrane (Bio-Rad). After blocking with
1% Boehringer blocking reagent (Roche) in PBS, HPSE protein was
detected by incubation with HPA1 for 1 h (ProsPecTany, 1:700),
followed by a 1-h incubation with a peroxidase-conjugated
secondary antibody (Santa Cruz Biotechnology, Heidelberg, Ger-
many, 1:8000). HPSE protein was visualized using a chemilumines-
cence substrate (Perbio Science, Etten-Leur, The Netherlands) and
enhanced chemiluminescence hyperfilm (Amersham Biosciences,
Buckinghamshire, UK).
Statistical analysis
Values are expressed as means7s.d. or as medians with ranges when
appropriate. Comparison of expression levels between the different
groups was evaluated using the non-parametric Mann–Whitney
U test. The non-parametric Spearman’s rank test was used to
calculate correlation between the different variables. A value of
Po0.05 was considered significant. We used GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA, USA) for the analysis of
our data.
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